Eligard Alternatives Compared
| Eligard (leuprolide) | Pluvicto (lutetium lu 177 vipivotide tetraxetan) | Bicalutamide |
|
|---|
| Eligard (leuprolide) | Pluvicto (lutetium lu 177 vipivotide tetraxetan) | Bicalutamide |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Prostate Cancer. Eligard may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Prostate Cancer. Pluvicto may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Prostate Cancer. Bicalutamide may also be used for purposes not listed in this medication guide. |
Related suggestions Prostate Cancer
Popular comparisons
|
|||||||||||||||||||||||
| More about Eligard (leuprolide) | More about Pluvicto (lutetium lu 177 vipivotide tetraxetan) | More about Bicalutamide | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Eligard has an average rating of 4.5 out of 10 from a total of 41 ratings on Drugs.com. 22% of reviewers reported a positive effect, while 44% reported a negative effect. |
Pluvicto has an average rating of 8.0 out of 10 from a total of 3 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 0% reported a negative effect. |
Bicalutamide has an average rating of 8.4 out of 10 from a total of 13 ratings on Drugs.com. 85% of reviewers reported a positive effect, while 8% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Eligard side effects |
View all Pluvicto side effects |
View all Bicalutamide side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Eligard prices |
View all Pluvicto prices |
View all Bicalutamide prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other leuprolide brands include: Camcevi, Fensolvi, Lupron, Lupron Depot, Lupron Depot-PED, Lutrate Depot |
N/A |
Casodex | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
4.25 hours |
41.6 hours |
240 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 284 drugs are known to interact with Eligard:
|
A total of 220 drugs are known to interact with Pluvicto:
|
A total of 383 drugs are known to interact with Bicalutamide:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
March 23, 2022 |
October 04, 1995 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.